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Neuronal-derived extracellular vesicles are enriched in the brain and serum of
HIV-1 transgenic rats
Raghubendra Singh Dagura, Ke Liao a, Susmita Sila, Fang Niu a, Zhiqiang Sunb, Yuri L. Lyubchenkob,
Eric S. Peeples c, Guoku Hua and Shilpa Buch a
aDepartment of Pharmacology and Experimental Neuroscience, University of Nebraska Medical Center, Omaha, NE, USA; bDepartment of
Pharmaceutical Sciences, University of Nebraska Medical Center, Omaha, NE, USA; cDepartment of Pediatrics, University of Nebraska Medical
Center, Omaha, NE, USA
ABSTRACT
Despite the efficacy of combination antiretroviral therapy (ART) in controlling human immuno-
deficiency virus (HIV-1) replication, cytotoxic viral proteins such as HIV-1 transactivator of tran-
scription (Tat) persist in tissues such as the brain. Although HIV-1 does not infect neuronal cells, it
is susceptible to viral Tat protein-mediated toxicity, leading to neuroinflammation that underlies
HIV-associated neurocognitive disorders (HAND). Given the role of extracellular vesicles (EVs) in
both cellular homoeostasis and under pathological conditions, we sought to investigate the
alterations in the quantity of neuronal-derived EVs in the brain – as defined by the presence of
cell adhesion molecule L1 (L1CAM) and to evaluate the presence of L1CAM+ EVs in the peripheral
circulation of HIV-1 transgenic (HIV-1 Tg) rats. The primary goal of this study was to investigate
the effect of long-term exposure of HIV-1 viral proteins on the release of neuronal EVs in the brain
and their transfer in the systemic compartment. Brain and serum EVs were isolated from both
wild type and HIV-1 Tg rats using differential ultracentrifugation with further purification using
the Optiprep gradient method. The subpopulation of neuronal EVs was further enriched using
immunoprecipitation. The current findings demonstrated increased presence of L1CAM+ neuro-
nal-derived EVs both in the brain and serum of HIV-1 Tg rats.
ARTICLE HISTORY
Received 25 July 2019
Revised 6 November 2019
Accepted 5 December 2019
KEYWORDS
Extracellular vesicles; HIV-1;
neuronal EVs; serum EVs;
brain EVs
Introduction
While antiretroviral therapy (ART), the cornerstone for
treatment of HIV-1 infection, has been effective in
controlling peripheral viraemia in HIV-1 infected indi-
viduals, inability of some of these drugs to cross the
blood-brain barrier (BBB), however, leads to persis-
tence of low-level virus replication in the central ner-
vous system (CNS) [1,2]. Additionally, ART treatment
fails to impact the production of early cytotoxic viral
proteins such as Tat, thereby leading to a neuroinflam-
matory milieu in the brain, which is one of the hall-
mark features of HIV-associated neurological disorders
(HAND) [3,4]. HAND affects almost 30–60% of
infected individuals and comprises clinical symptoma-
tology ranging from asymptomatic to minor cognitive
motor disorders [5–8]. Based on the understanding
that the cognitive decline associated with HAND
reflects neuronal damage and the fact that neurons
are not infected by HIV-1, mechanism(s) other than
direct infection are likely suggestive of the underlying
neuropathogenesis.
Recent evidence has implicated the role of extracellular
vesicles (EVs) as contributors to the pathogenesis of var-
ious neurodegenerative diseases including Alzheimer’s
(AD) and Parkinson’s diseases (PD) [9–12]. EVs, including
exosomes (50–200 nm) are composed of membrane pro-
teins and lipids, as well as cytoplasmic components of the
cell from which they originate, such as mRNA and
miRNA, organelles or infectious particles [13–18]. Many
studies have suggested a bidirectional transport of EVs
from the brain to the systemic circulation via the BBB
[19–21]. For example, systemic delivery of EVs from den-
dritic cells (DCs) loaded with the small interfering RNA
(siRNA) were used as therapeutic vehicles to treat a mouse
model of Alzheimer’s disease [21], suggesting thereby the
ability of these vehicles to cross the BBB and deliver the
siRNA cargo into target cells for specific gene knockdown
[22]. In another study EVs derived from a mouse lym-
phoma cell line were demonstrated to deliver curcumin
across the BBB into microglial cells via the intranasal
administration route to attenuate neuroinflammation and
autoimmune responses in an experimental autoimmune
encephalomyelitis (EAE) model [23].
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Over the past years search for brain-derived EVs as
peripheral non-invasive biomarker(s) for neurodegenera-
tive diseases has gained momentum [24,25]. Based on the
premise that in the CNS the expression of cell adhesion
molecule L1CAM is primarily restricted to neurons, the
presence of this protein in the exosomes demonstrates its
neuronal origin [26–28]. EVs derived from cultured cor-
tical neurons have been demonstrated to exhibit cell
adhesion molecule L1 (L1CAM) on their surface, with
implications for various neurodegenerative diseases [28].
In fact, increased release and transit of L1CAM+ EVs via
the blood brain barrier has been reported in the plasma of
HIV+ patients, suggesting their role as a liquid biopsy
biomarker [29]. Additionally, L1CAM+ EVs have also
been identified in both melanoma cells [30], and in ovar-
ian cancer [31]. Neuronal enrichment of EVs has the
benefit of improving the signal to noise ratio, increase
the measurement sensitivity, lower the detection thresh-
old (by providing an enriched fraction containing higher
concentrations of target molecule compared with plasma
or total EVs), and better reflect the pathophysiological
processes occurring in the CNS. Elegant studies have
demonstrated the presence of p-T181-tau and p-T231-
tau in both plasma and serum-derived L1CAM+ EVs, that
were not detectable in either the serum or plasma samples
even using a sensitive electrochemiluminescence-based
assay [25,28,29]. Intriguingly, Lamontagne-Proulx et al.
have also identified specific signature proteins in the
plasma EVs that could reliably differentiate control sub-
jects from mild or moderate in patients with PD [32].
These studies thus suggest that EVs and their cargo not
only play a role in the onset of various diseases but could
also serve as excellent indicators for disease progression.
In the present study, we employed the HIV-1 trans-
genic (Tg) rat model that constitutively expresses 7 of
the 9 HIV-1 proteins including Tat, to evaluate the
effect of viral proteins on the release of neuronal-origin
L1CAM+ EVs in both the extracellular space of the
brain as well as serum. Our findings suggest increased
release of neural-derived EVs in both brain as well as in
the serum of HIV-1 Tg rats compared to the wild type
(WT) controls.
Materials and methods
Animals
HIV-1 Transgenic rats were purchased from Harlan
Laboratories (Indianapolis, Indiana, USA) and were gen-
erated using a non-infectious provirus expressing HIV-1
viral proteins, such as Tat, Env, Rev, Nef and Vif. In these
animals, viral proteins are continually expressed through-
out the lifespan of the animal. Presence of Nef and the
other viral proteins has been suggested in the blood,
lymph nodes, spleen and CNS of these HIV-1Tg rat
[33–35]. In these Tg animals, expression of mRNA levels
of viral proteins in the spinal cord, cerebellum, and stria-
tumwere found to be significantly higher in the older rats
compared with younger animals, thus suggesting age-
dependent differential expression of various HIV viral
proteins [34]. Given the higher prevalence of HIV-asso-
ciated neurocognitive impairment in women versus men
(52% vs 41%) [36], female animals were evaluated in the
present study. Female HIV-1 transgenic Sprague Dawley
rats (HIV-1 Tg, F344; 12–18 months age) were selected
due to the fact that the HIV-1 Tg rats express increased
levels of viral proteins by 11–12 months of age in the
brain that is accompanied with the gradual development
of AIDS-related neuropathologies [34]. Age and back-
ground-matched wild-type controls (Fischer 344 WT)
were also used in the study. Animals were housed in
clean polypropylene cages under conditions of constant
temperature and humidity, with a 12 h light and 12 h
night cycle, during which time they had free access to
food and water ad libitum. All animal procedures were
performed following the protocols approved by the
University of Nebraska Medical Centre (UNMC)
Institutional Animal Care and Use Committee.
Isolation of EVs from hemibrain
Whole brains were extracted from Fischer 344 WT and
HIV-1 Tg female rats (n = 5 each group) at 12–18 months
of age following rapid decapitation and kept frozen at −80°
C until further processing. Hemibrains were homogenized
in 10–15 mL of activating solution consist of Hibernate A
medium with proteolytic enzyme papain (20 units/mL)
and incubated at 37°C for ~30 min on gentleMACS Octo
Dissociator with heaters (Miltenyi Biotec, USA) using
inbuilt 37C_ABDK_1 Program. Following homogeniza-
tion, the suspension was centrifuged at 300 x g for
10 min, and then at 2000 x g for 10 min at 4°C to eliminate
tissue fragments and cells, dead cells and debris, respec-
tively. Supernatants were then filtered through 0.8 µm
filters, and further centrifuged at 10,000 x g for 30 min to
discard unwanted large vesicles. The supernatant was then
filtered through 0.2 μm filters and ultracentrifuged at
100,000 x g for 70 min at 4°C in an SW32 Ti rotor to
concentrate small EVs. EV pellets were resuspended in
500 µL of 0.25 M sucrose buffer [10 mM Tris, pH 7.4]
for gradient purification. Top-loaded sedimentation gradi-
ents were performed on 5, 10, 20 and 40% iodixanol
(Optiprep; Cosmo Bio USA) gradient as previously
described [37,38]. Briefly, three mL of high-density iodix-
anol (40%) was first transferred to the bottom of a 14 mL
ultracentrifugation tube. Subsequently, 20, 10 and 5% of
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iodixanol (each 3 mL) were layered, and 500 µL of resus-
pended EVs were loaded on top. Gradients were ultracen-
trifuged at 100,000 x g in an SW40 Ti rotor for 18 h. After
discarding 500 µL from the top, 12 fractions of 1 mL were
taken from the top of the gradient (named F1-F12), diluted
in phosphate-buffered saline (PBS), and pelleted again for
one hour at 100,000 x g in an SW40 Ti rotor to get rid of
iodixanol from the samples. Alternatively, iodixanol frac-
tions were pooled and resuspended in sterile 1 x PBS,
followed by ultracentrifugation for 70 min at 100,000 x g
in an SW32 Ti rotor (Beckman) to pellet EVs for the
removal of iodixanol for immunoprecipitation of
L1CAM+ neuronal EVs [29].
Isolation of EVs from serum
Serum collection and EV isolation from blood were in
accordance with guidelines published previously [39,40].
Briefly, blood was collected in 6 mL serum tubes (BD
Vacutainer, USA) from 344 WT and HIV-1 Tg rats at
12–18months of age by cardiac puncture after euthanizing
animals. We had 8–10 female rats in each group. Blood
was centrifuged at room temperature at 2500 x g for
15 min to collect serum and subsequently underwent
another centrifugation step at 2500 x g for 15 min in a
clean plastic tube. EVs were isolated by ultracentrifugation
and purification by iodixanol density gradient, as reported
previously [41,42].
Enrichment of L1CAM+ EVs from brain-and serum-
EVs
Enrichment of L1CAM+ EVs was performed by
immunoprecipitation using a biotinylated antibody
specific for neuronal surface marker to isolate a sub-
population of L1CAM+ EVs as described previously
[28,43,44]. Briefly, 50% of pooled F1-F7 fractions from
the brain fraction and F6-F10 fractions from the
serum fraction were incubated overnight at 4°C with
4 μg of rabbit anti-rat L1CAM biotinylated antibody
(LS Bio, USA; LS-C470565) in 100 μL of 3% bovine
serum albumin (BSA) and bound to 25 μL of
Streptavidin-plus ultra-link resin (ThermoFisher,
USA) for 1 h at 4°C. After centrifugation at 3000 x g
for 5 min at 4°C and removal of the supernatant
(L1CAM− EV fraction), pellet were suspended in
90 μL of 0.1 M glycine-HCl (pH 2.8) to release EVs
in the supernatant and neutralized with 10 μL of 1 M
Tris-HCl (pH 8.0). Neuron-derived EVs were counted
using zeta view and were subsequently used for wes-
tern blotting.
Atomic force microscopy
Atomic force microscopy was performed to character-
ize the topography of extracellular vesicles as described
previously [14]. Briefly, 20µL (9–12 × 1011 EVs/mL) of
EV sample was deposited on APS mica for 20 min at
room temperature. Then 200 μL of the PBS buffer was
added to the sample. The sample was then subjected to
atomic force microscopy (AFM) imaging using the
Asylum Research MFP3D (Santa Barbara, CA, USA)
instrument. Imaging was performed in tapping mode
at room temperature. An MSNL probe with cantilever
“E” (Bruker Corporation) was employed for imaging.
The nominal spring constant of the MSNL “E” canti-
levers was ∼0.1 N/m.
Zetaview tracking analysis
Nanoparticle tracking analysis (NTA) was performed
using ZetaView Nanoparticle Tracking Analyser (Particle
Metrix, Germany) and its corresponding software
(ZetaView 8.04.02 SP1) to analyse EVs isolated from
brain and serum samples, as published previously [45].
Briefly, 100 nm polystyrene nanostandard particles were
used to calibrate the instrument before sample readings.
Cell quality check and instrument alignment and focus
were first performed prior to ZetaView for sample mea-
surements using the software. For video acquisition, cam-
era setting sensitivity was set to 85, shutter speed of 100
and a frame rate of 30 were used according to the system’s
software guidance. For each sample, 1 mL of the sample,
diluted in 0.20 μm filtered PBS was loaded into the cell.
The instrument measured each sample at 11 different
positions throughout the cell, with 2 cycles of readings at
each position. After automated analysis and removal of
any outliers from the 11 positions, the size (diameter in
nm) and the concentration (particles/mL) of the sample
was calculated by themachine software.Measurement data
from the Zeta Viewwere analysed using the corresponding
Zeta view software, and Microsoft Excel 2016. Final con-
centration was calculated by multiplying the observed
concentration with the dilution factor.
Immunoblot analysis
EVs derived from equal amount (brain) and equal volume
(serum) were lysed in 10x RIPA lysis buffer [150 mM
NaCl, 1% Triton X-100, 50 mM Tris (pH 7.6), 0.1% SDS,
5 mM EDTA, 0.5% sodium deoxycholate] with the addi-
tion ofHALT protease and phosphatase inhibitor. Proteins
were extracted by sonication. For confirmation of EV
proteins in purified lysates, 5X Laemmli sample buffer
[10% SDS, 250 mM Tris pH 6.8, 1 mg/mL bromophenol
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blue, 0.5 M DTT, 50% glycerol, 5% BME] was added to
EVs. For immunoblot, proteins were electrophoresed in a
sodium dodecyl sulphate-polyacrylamide gel (10–12%)
under reducing conditions followed by transfer to PVDF
membranes. Blots were probed with Alix (Abcam, USA);
TSG101 (Abcam, USA); CD9 (Abcam, USA); Calnexin
(Sigma, USA); L1CAM (LifeSpan Biosciences, USA), and
βIII Tubulin (Biolegend, USA). The secondary antibodies
were HRP conjugated to goat anti-mouse (Santa Cruz,
USA)/rabbit IgG (Santa Cruz, USA). Images were acquired
on FluorChem M FM0243 (Protein Simple, USA).
Statistical analysis
Significant differences in total EVs, neuronal-origin
EVs harvested from WT and HIV-1 Tg brains and
sera were determined by unpaired parametric student’s
t-test with Welch’s correction and as mentioned in the
respective figure legends.
Results
Purification and characterization of EVs from brain
extracellular space
EVs were isolated from brain extracellular space by
enzymatic digestion, differential centrifugation, and
purification by Optiprep density gradient centrifuga-
tion as shown in the schematic in Figure 1(a). Size
distribution assessed by zeta view revealed that 90%
of particles distributed in the range of 50 to 200 nm,
with a peak at ~110 nm. The observed heterogenicity in
the size of particles is shown in a representative cap-
tured image from the video acquired on zeta view
(Figure 1(b)). More than 95% of EVs with a size
range of 50–200 nm were present in fractions F1-F7
(Figure 1(c)). The topography of F1-F7 EVs was
assessed under the tapping mode by immobilizing vesi-
cles on positively charged APS-mica surface for atomic
force microscopy (AFM) analysis. Intact EVs that could
be immobilized electrostatically presented a median
size of 26.9 nm in height (Figure 1(d)). Western blot-
ting of brain-derived EVs demonstrated positivity for
exosome-enriched proteins Alix, TSG 101 and CD9
specifically in F1-F7 fractions and negative for endo-
plasmic reticulum protein calnexin. Brain-lysate was
used as a positive control for calnexin (Figure 1(e)).
Neuronal-derived EVs are enriched in the brains of
HIV-1 transgenic rats
Based on the premise that L1CAM+ neuron-derived
EVs are enriched in neurodegenerative diseases, we
next sought to investigate alterations in L1CAM+ EVs
of neuronal origin ex vivo in the context of HIV-1 viral
proteins. To check the neuronal origin of EVs, the
subpopulation of L1CAM+ EVs were immunoprecipi-
tated from pooled F1-F7 fractions of EVs isolated from
the brain lysates of HIV-1 Tg and WT using biotiny-
lated antibodies against the neuronal surface marker.
Neural cell adhesion molecule L1CAM was selected
owing to its high and relatively specific expression in
neural tissues [28,29]. The results from zeta-view
demonstrated increased numbers of EVs in the pooled
fractions (F1-F7) of HIV-1 Tg rats compared with that
from the WT rats; this however, was not statistically
significant (Figure 2(a)). Similarly, there were signifi-
cantly increased numbers of L1CAM+ EVs isolated
from pooled F1-F7 fractions from HIV-1 Tg rats
(mean value of 3.71 x 106/mg [range 4.86 × 105 to
1.01 × 107 EVs/mg]) compared with those isolated
from pooled fractions of WT rats (mean value of
EVs 3.71 x 105/mg [range 3.01 × 105 to 4.36 × 105)
(Figure 2(b)). Pooled F1-F7 EVs and L1CAM+EVs
from HIV-1 Tg rats had a similar size distribution as
the WT rats (range ~ 50 to 200 nm; Figure 2(c)). The
concentration of L1CAM+EVs however, was noticeably
higher in HIV-1 Tg rats (mean value 1.84 × 104 EVs/
mg) compared with the WT rats (1.85 x 105 EVs/mg;
Figure 2(d)). We also confirmed the presence of
L1CAM on EVs using antibodies against L1CAM
tagged with biotin by western blotting (Figure 2(e)).
Similar to previous studies, we observed cleaved form
(~70, ~55 and ~30 kDa) of L1CAM in L1CAM+ EVs
[46,47]. Further, we confirmed the presence of another
neuronal marker βIII Tubulin as well as exosomal
markers TSG101 and CD9 on the L1CAM+ EVs
(Figure 2(e)). For Western blotting L1CAM+ EVs
derived from equal amount of brains were lysed in
RIPA lysis buffer and loaded onto the gels. For normal-
ization of EVs, brain lysates from both WT and HIV-1
Tg rats were probed with β-actin (Figure 2(f)).
Densitometry of neuronal proteins and exosome pro-
teins in L1CAM+ EVs fraction revealed increased
expression of L1CAM in HIV-1 Tg rats compared
with the WT controls when normalized with the
respective brain-lysate (input) (Figure 2(g)).
Purification and characterization of extracellular
vesicles from rat serum
We next sought to investigate whether, similar to an
increase in neuronal EVs in the brain of HIV-1 Tg
rats, there was also an increase in L1CAM+ EVs in the
serum. We first isolated and purified EVs from the
serum using a protocol similar to that for the brain-
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derived EVs as summarized in Figure 3(a). The findings
from zeta view demonstrated a more than 90% distribu-
tion of particle size in the range of 50 to 200 nm with a
peak at ~84 nm. Representative morphology of the EVs
is shown in the inset (Figure 3(b)). More than 95% of
EVs (ranging 50–200 nm) were present in fractions F6-
F10 (Figure 3(c)). Morphology of EVs (F6-F10) was
further assessed using AFM and showed heterogeneous
topography of EVs (Figure 3(d)). Additionally, western
blot was run to confirm the presence of exosomes in EVs
and results showed that serum-derived EVs were posi-
tive for exosome-enriched proteins Alix, TSG 101 and
CD9 specifically in fractions F6-F10 (Figure 3(e)).
Sera of HIV-1 Tg rats are enriched for neuronal
origin EVs
Based on the premise that L1CAM+ neuron-derived
EVs are released in the serum in neurodegenerative
diseases, we sought to investigate alterations in the
quantity of circulating L1CAM+ EVs in vivo in HIV-
1 Tg compared to WT rats. Given the relative speci-
ficity of L1CAM to neural tissue, we started with
pooled sera of 3–4 WT rats to ensure and maximize
the yield of EVs to identify L1CAM+ EVs and to
assess whether EVs of neuronal origin were present
in the serum.
Figure 1. Characterization of brain-derived EVs: (a) Extracellular vesicles (EVs) were isolated from the brain of WT rats (n = 2) by
enzymatic digestion and followed by series of centrifugation. For the purification, EVs were top-loaded on a 5–40% iodixanol and
ultracentrifuge at 100,000 g for 18 h. Twelve 1 mL fractions (F1–F12) were collected. (b) Size distribution of EVs for the size range
4–500 nm of F1-F12 fraction from 2 WT- rats are shown. Inset image showing EVs morphology captured from the video in zeta
view. (c) The graph shows the actual concentration of each fraction (F1-F12) assessed by zeta view after adjusting for dilutions.
(d) Topographic profiling of F1-F7 EVs using atomic force microscopy (AFM) under tapping mode revealed a heterogeneous
population of spherical particles. (e) Western blot images show protein expression from each fraction (F1-F12) for the presence of
EV-associated proteins ALIX, TSG101 and CD9 exosome marker and non-exosome marker calnexin.
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For this, we pooled equal amount of sera from WT
and HIV-1 Tg rats and counted the numbers of F6-F10
EVs and L1CAM+EVs isolated from total EVs as well
as pooled F6-F10 fractions, respectively. We observed
increased EV concentration in the F6-F10 fractions
isolated from the sera of HIV-1 Tg rats, with mean
value of 1.35 × 1010 EVs/mL (range 9.8 × 109 to
1.92 × 1010 EVs/mL) in HIV-1 Tg compared with
WT mean value 6.27 × 109 EVs/mL (range from
2.0 × 109 to 1.01 × 1010 EVs/mL) (Figure 4(a)). We
also observed an increase in the L1CAM+ neuronal EVs
in HIV-1 Tg rats with mean value 2.51 × 108 EVs/mL
(range 3.26 × 107 to 5.81 × 108 EVs/mL) as compared
to the WT mean value 1.29 × 108 EVs/mL (range
2.08 × 107 to 2.96 × 108 EVs/mL). The difference
between the two groups, however, was not statistically
significant (Figure 4(b)). The F6-F10 pooled EVs
(Figure 4(c)) and L1CAM+ EVs (Figure 4(d)) from
HIV-1 Tg rats had a size distribution similar to that
of the WT rats, in the range of 50 nm to 200 nm, with
median diameters of ~100 nm for F6-F10 EVs and
~110 nm for L1CAM+ EVs. The concentration of
each size, however, was considerably higher in the
HIV-1 Tg group (Figure 4c,d). The results from wes-
tern blots showed increased expression of L1CAM in
HIV-1 Tg L1CAM+ EVs compared to WT animals with
a concomitant increase in the expression of another
neuronal marker βIII Tubulin (Figure 4e,f). Similar to
brain L1CAM+ EVs, serum L1CAM+EVs also displayed
L1CAM fragments of ~70, ~55 and ~30 kDa. Exosome
markers were also confirmed in L1CAM+ EVs using
exosome markers TSG 101 and CD9 (Figure 4e,f).
Discussion
The advent of highly active antiretroviral drugs has sig-
nificantly reduced the incidence of most severe forms of
neurocognitive impairment, including HIV-1-associated
dementia; however, milder forms of neurocognitive
impairment continue to afflict ~ 40 and 60% of HIV-1
Figure 2. Neuronal-derived EVs are enriched in the brain of HIV-1 transgenic rats. (a) Graph showing the concentration of pooled
F1-F7 fractions obtained from the brains of WT and HIV-Tg rats (n = 4), as evaluated by zeta-view. Equal amounts of brains from WT
and HIV-1 Tg rats were used as the starting material to isolate total EVs. All conditions and dilutions were kept identical in both the
groups (Wt and HIV-1 Tg) for further isolation of F1-F7 EVs and for L1CAM+ EVs. * p < 0.05 by unpaired parametric student’s t-test
with Welch’s correction. (b) Graph shows the actual concentration of EVs in the L1CAM+ EVs fractions obtained by immunopre-
cipitation of pooled F1-F7 fractions of WT and HIV-1 Tg rats (n = 3), evaluated by zeta view. (c) Size distribution of F1-F7 fractions,
and (d) L1CAM+EVs was examined by nano track analysis using zeta view. Figures depict the actual concentration of EVs by
adjusting for the dilution factor in the range of 50–200 nm. (e) Western blot images showing increased expression of neuronal
markers (L1CAM, βIII tubulin) in L1CAM+ EVs from HIV-1 Tg rat compared to L1CAM+ EVs from WT rat (n = 5 each group). L1CAM+
EVs derived from the brains (equal weights) from each group were loaded onto the gel. Representative L1CAM+ EVs from one WT
and one HIV-1 Tg rat are shown. CD9, TSG101 were used as a positive control for exosomes. (f) Brain lysate was used as input (1% of
total brain lysate) and β-actin from brain lysates (input) was used as endogenous control for the brain-derived EVs. (g) Densitometry
of proteins in L1CAM+EVs fractions of WT and HIV-1 Tg rats normalized with brain lysate β actin (input). Graph for L1CAM expression
shows densitometry of ~55 kDa band. *p < 0.05 by multiple t-test using the Holm-Sidak method.
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seropositive individuals [5]. The data presented in this
study demonstrate a significant enrichment of neuronal
origin EVs (L1CAM+ EVs) in the extracellular space of the
brain with also a concomitant increase of these in the sera
of HIV-1 Tg rats compared to the WT animals. In accor-
dance with previous studies demonstrating that HIV-1
infected individuals display increased plasma EVs com-
pared with healthy controls (Hubert et al., 2015), we also
identified increased numbers of circulating total EVs in the
HIV-1 Tg rat compared with the WT group.
The choice of animal models in studying HAND has
been fraught with limitations since HIV-1 does not
infect rodents. While none of the models developed
can recapitulate the human syndrome of HAND, several
small animal models have been exploited to address
specific questions and aspects of HAND pathogenesis
Figure 3. Isolation and characterization of EVs from rat serum. (a) Extracellular Vesicle (EVs) isolation and purification procedure by
ultracentrifugation. EVs obtained after centrifugation at 100,000 x g were resuspended, top-loaded on a 5–40% on iodixanol
(Optiprep) and ultracentrifuge at 100,000 x g for 18 h. Twelve 1 mL fractions (F1–F12) were collected. (b) Size distribution graph
shows the distribution of F1-F12 EVs fractions in the size range of 4–500 nm from WT-rats (n = 2). Inset showing representative EVs
morphology captured from the video in zeta view. (c) Final concentration of EVs obtained from 6 wild-type rats pooled serum
(n = 2; n refers to pooled serum from 3 rats and represented by one symbol) for each fraction (F1-F12) followed by density gradient
ultracentrifugation was analysed by Zeta View. (d) Atomic force microscopy (AFM) image of pooled F6-F10 fractions EVs. (e) Proteins
from each fraction (F1-F12) of and F1-12 EVs were analysed by western blot for the presence of EV-associated proteins ALIX, TSG101
and CD9.
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[48,49]. Herein we chose to focus on the HIV-1 Tg rats
that constitutively express 7 of the 9 viral proteins
throughout the lifespan. These rats ideally mimic the
human scenario of HIV-1-infection in the presence of
cART, with substantially suppressed viraemia but
ongoing presence of viral proteins even in the CNS,
resulting likely from the ongoing low-level virus replica-
tion in viral reservoirs [50,51]. Another advantage of
these rats is their ability to recapitulate some of the
behavioural cognitive deficits of HAND [34,35,52].
Despite its utility in studying HAND, and allowing us
to assess the impact of viral proteins on HAND, one of
the major limitations of this model is that it is not an
infectious model, thus necessitating the importance of
validating our findings in more relevant model system.
We thus sought to confirm our rodent findings in the
serum of HIV+ patients on cART. Similar to findings in
the rat model, a previous study by Chettimada et al.
demonstrated elevated levels of EVs and exosomal mar-
kers in the plasma of HIV-1 infected patients compared
to that of the healthy controls [53].
For this study, we chose to use a combination of EV
isolation and purification methods involving both differ-
ential ultracentrifugation as well as the well-established
iodixanol (Optiprep) gradient ultracentrifugation
approaches from the brain and serum, and also followed
the minimal information for studies of extracellular vesi-
cles 2018 (MISEV2018) guidelines for EV characteriza-
tion [38,40]. Previous studies have reported the use of
other isolation/purificationmethods such as precipitation
solution-based ExoQuick and total exosome isolation. A
study performed by Van Deun et al., demonstrated ele-
vated levels of exosomal marker proteins (Alix, HSP90α,
HSP70, TSG101, and CD63) by western blot analysis in
lysates from centrifugation-based (ultracentrifugation
and optiprep density gradient) methods compared with
the precipitation solution-based ExoQuick and total exo-
some isolation methods [54].
Neuronal enrichment of EVs (L1CAM+ EVs) has
been suggested to improve the signal to noise ratio
and lower the detection threshold when assessing
brain-specific serum EV expression in several
Figure 4. Neuronal EVs are enriched in the sera of transgenic rats. (a) Graph shows the concentration of EVs (F6-F10 fractions)
isolated from equal amount of pooled sera from WT rats (n = 5, each n is equivalent to pooled serum of 3–4 rats) and HIV-1 Tg rats
(n = 3, each n is equivalent to pooled serum of 3–4 rats). All conditions and dilutions were kept identical for both the groups (Wt
and HIV-1 Tg) for further isolation of F6-F10 EVs and L1CAM+ EVs. * p < 0.05 by unpaired parametric student’s t-test with equal
standard deviation. (b) Graph shows the concentration of EVs from the L1CAM+ EVs fractions using zeta view and obtained from
immunoprecipitation of pooled F6-F10 fractions of Wt and HIV-1 Tg rats (n = 3, each n is equivalent to pooled serum of 3–4 rats). (c)
Size distribution of F6-F10 fractions and (d) L1CAM+EVs was examined using zeta view. Figures depict the actual concentration of
EVs by adjusting with the dilution factor in the range of 50–200 nm. (e) Western blot images show increased expression of neuronal
markers (L1CAM, βIII Tubulin) in L1CAM+ EVs from HIV-1 Tg rats when compared to L1CAM+ EVs from WT rats. Equal amount of
serum was used as the starting material to derive L1CAM+ EVs. Equal volume of EVs (40 uL) after adjusting the obtained L1CAM+
volume to equal to parent F6-F10 EVs fraction was used to load the gel. TSG 101 and CD9 were used as positive controls for
exosome marker. (f) Densitometry of the proteins in relation to WT rats. Graph for L1CAM expression shows densitometry of
~55 kDa band. * p < 0.05 by unpaired parametric student’s t-test using Mann-Whitney test.
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neurodegenerative diseases [29,43,55]. The 220-kDa
full-length molecule L1CAM is proteolytically pro-
cessed at different sites by different enzymes, leading
to generation of differently sized cleaved products of
~140, ~80, ~70, ~55 and ~30 kDa, and serves as a
substrate for regulating intramembrane proteolysis
[46,56,57]. Ectodomain shedding of L1CAM yields a
C-terminal stub (L1-32), which is retained in the
plasma membrane [57], with the ectodomain cleavage
of membrane molecules accelerated under pathological
conditions involving neurodegeneration [58]. Lutz et
al. showed that the 70 kDa fragment generated from
serine protease-dependent cleavage of full-length
L1CAM at the plasma membrane was transported
from the plasma membrane to a late endosomal com-
partment cleavage with alterations in the levels of the
fragment that were found to be associated with neuro-
degeneration [56]. The 70 kDa L1CAM fragment can
also be cleaved into a sumoylated ~30 kDa cytosolic
fragment [46]. To detect the biotinylated fragment after
its release in EVs, biotinylated proteins were isolated
from these fractions using streptavidin beads and ana-
lysed for the presence of the biotinylated fragments by
western blot analysis using c-terminal antibody.
Interestingly, we observed the L1CAM cleaved form
(~ 70, ~55 and ~30 kDa) in L1CAM+ EVs derived
from both brain and sera, suggesting the ectodomain
cleavage of full-length L1CAM, as previously reported
[46,47]. Similar to our findings, L1CAM fragment of
55 kDa was also observed in EVs isolated from cell
culture supernatants after cell surface biotinylation and
L1 stimulation of neuroblastoma cells [56]. We also
confirmed the L1CAM+ EVs for their neuronal origin
by assessing for another neuronal marker βIII tubulin.
We observed an increase in purified EVs and L1CAM+
neuronal EVs in both the brain and sera of HIV-1 Tg
rats compared with the WT rats, thereby suggesting
increased shedding and transport in the periphery of
the neuronal origin EVs in the context of viral proteins.
In this study, we demonstrate the feasibility of
L1CAM+ EV isolation from the brain and sera of
HIV-1 Tg rats, suggesting use of HIV-1 Tg rats as
a viable model for future studies involving EV sig-
nalling in HIV-associated brain injury. Circulating
neuronal exosomes hold a great promise to evaluate
the neurotoxicity, pathophysiology of neurons and
progressive neurodegeneration prior to the develop-
ment of symptoms.
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